Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Related Keywords

United States ,San Antonio ,Texas ,New Jersey ,East Hanover ,America ,Isabella Zinck ,Thomas Hungerbuehler ,Ashley Buford ,Samir Shah ,Julie Masow ,Parag Mahanti ,Sloan Simpson ,Alina Levchuk ,Virtual Scientific Program ,Twitter ,Novartis Oncology Communications ,Novartis Us External Communications ,Novartis External Communications ,Novartis ,Exchange Commission ,Novartis Pharmaceuticals ,Novartis Pharmaceuticals Corporation ,Cancer Genome Atlas Network ,University Of California San Francisco ,Novartis Pharmaceuticals Corp ,Helen Diller Family Comprehensive Cancer Center ,Antonio Breast Cancer Symposium ,Breast Oncology ,Clinical Trials Education ,California San Francisco ,Helen Diller Family Comprehensive Cancer ,Scientific Program ,Advanced Breast ,Safety Informationfrom ,San Antonio Breast Cancer Symposium ,Cancer Genome Atlas ,Aromatase Inhibitor Resistance ,Circulating Tumour ,Metastatic Breast ,Alpelisib Plus Fulvestrant ,Participants With ,Advanced Breast Cancer After Treatment With ,Aromatase Inhibitor ,Study Assessing ,Subjects With Advanced ,Carry Either ,Two Part ,Placebo Controlled Study ,Combination With Trastuzumab ,Maintenance Therapy ,Patients With ,Advanced Breast Cancer With ,Alpelisib Plus Olaparib ,High Grade Serous Ovarian Cancer ,Investegate Announcements ,Investegate Company Announcements ,Ovartis Ag Chf0 50 Regd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,